PFOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trial - Université de Bourgogne Accéder directement au contenu
Communication Dans Un Congrès Année : 2017

PFOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trial

Domaines

Cancer

Dates et versions

hal-01632415 , version 1 (10-11-2017)

Identifiants

Citer

J-B. Bachet, O. Lucidarme, C.B. Levache, E. Maillard, J.L. Raoul, et al.. PFOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trial. the 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. pp.505P, ⟨10.1093/annonc/mdx393.031⟩. ⟨hal-01632415⟩
52 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More